NASDAQ:GNOM Global X Genomics & Biotechnology ETF (GNOM) Price, Holdings, & News $46.39 +0.03 (+0.06%) As of 05/8/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsShort InterestTrendsBuy This Stock About Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GNOM alerts:Sign Up Key Stats Today's Range$46.17▼$46.8550-Day Range$41.40▼$47.7852-Week Range$29.44▼$51.42Volume7,125 shsAverage Volume8,431 shsMarket Capitalization$51.96 millionAssets Under Management$58.83 millionDividend YieldN/ANet Expense Ratio0.50%Aggregate RatingModerate Buy ETF Overview Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center. Its customers include some of the global academic and government research centers and biopharmaceutical companies. Effective March 18, 2013, BGI-Shenzhen announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has completed the acquisition of the Company. Read More Global X Genomics & Biotechnology ETF ExpensesTypeGNOMTheme ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.50%0.57%0.57%0.54%0.53%Other Expenses0.00%0.57%0.55%0.51%0.55%Total Expense0.50%0.73%0.76%0.73%0.73%Fee Waiver0.00%-0.74%-0.64%-0.50%-0.61%Net Expense0.50%0.60%0.63%0.62%0.60% Receive GNOM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Global X Genomics & Biotechnology ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNOM ETF News HeadlinesGlobal X Genomics & Biotechnology ETF (NASDAQ:GNOM) Shares Cross Above Two Hundred Day Moving Average - What's Next?May 5, 2026 | americanbankingnews.comGlobal X Genomics & Biotechnology ETF declares semi-annual distribution of $0.0083June 30, 2025 | msn.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.May 9 at 1:00 AM | Profits Run (Ad)10x Genomics Misses Revenue ForecastOctober 29, 2024 | fool.comGlobal X Genomics & Biotechnology UCITS ETF (GNOM.L)August 18, 2024 | finance.yahoo.comGNOM Global X Genomics & Biotechnology ETFJuly 25, 2024 | seekingalpha.comSee More Headlines GNOM ETF - Frequently Asked Questions How have GNOM shares performed this year? Global X Genomics & Biotechnology ETF's stock was trading at $45.46 at the beginning of the year. Since then, GNOM stock has increased by 2.0% and is now trading at $46.39. When did Global X Genomics & Biotechnology ETF's stock split? Global X Genomics & Biotechnology ETF shares reverse split on Tuesday, September 2nd 2025.A 1-4 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 1st 2025. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. Who are Global X Genomics & Biotechnology ETF's major shareholders? Top institutional shareholders of Global X Genomics & Biotechnology ETF include Wealth Management Partners LLC (0.50%). How do I buy shares of Global X Genomics & Biotechnology ETF? Shares of GNOM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Global X Genomics & Biotechnology ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Global X Genomics & Biotechnology ETF investors own include Meta Platforms (META), NVIDIA (NVDA), Teladoc Health (TDOC), Intel (INTC), Alibaba Group (BABA) and PayPal (PYPL). Fund Details IssuerGlobal X Fund NameGlobal X Genomics & Biotechnology ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:GNOM Inception Date4/5/2019 Fund ManagerChang Kim, James Ong, Nam To, Wayne Xie Webwww.completegenomics.com Phone+1-650-9432800Fund Focus Asset ClassEquity BenchmarkSolactive Genomics Index CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings50 Fund Statistics Assets Under Management$58.83 million Average Daily Volume$0.00 Discount/Premium-0.12% Administrator, Advisor and Custodian AdministratorGlobal X Management Company LLC AdvisorGlobal X Management Company LLC CustodianBrown Brothers Harriman & Co. DistributorSEI Investments Distribution Co. Transfer AgentBrown Brothers Harriman & Co. TrusteeN/A Lead Market MakerSusquehanna Options OptionableOptionable Options Volume1 Put Options1 Call Options1 Short Interest6,100 shs Miscellaneous Outstanding Shares1,120,000Beta1.19 Creation Unit50,000 Creation Fee$500.00 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report Top 10 GNOM HoldingsModerna (NASDAQ:MRNA)Holding Weight: 7.62%Arrowhead Pharmaceuticals (NASDAQ:ARWR)Holding Weight: 7.50%Praxis Precision Medicines (NASDAQ:PRAX)Holding Weight: 6.60%Illumina (NASDAQ:ILMN)Holding Weight: 5.66%Guardant Health (NASDAQ:GH)Holding Weight: 4.95%Natera (NASDAQ:NTRA)Holding Weight: 4.42%BioMarin Pharmaceutical (NASDAQ:BMRN)Holding Weight: 4.04%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 3.95%BioNTech (NASDAQ:BNTX)Holding Weight: 3.49%Legend Biotech (NASDAQ:LEGN)Holding Weight: 3.45%Full Holdings DetailsGNOM Sector ExposureGNOM Industry Exposure This page (NASDAQ:GNOM) was last updated on 5/9/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredElon’s AI supercomputer just went live. Here’s my #1 stock.Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...InvestorPlace | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Global X Genomics & Biotechnology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Global X Genomics & Biotechnology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
